FDA clearance of IND application for iSCIB1+

Summary by AI BETAClose X

Scancell Holdings plc announced that the FDA has cleared its Investigational New Drug application for a Phase 3 trial of iSCIB1+ in advanced melanoma, with progression-free survival as the endpoint. Data from the 140-patient SCOPE Phase 2 trial showed iSCIB1+ achieved a 74% progression-free survival rate at 16 months in the target population, a 24-percentage point improvement over the current standard of care. The company plans to start the registrational Phase 3 trial in 2026 and is exploring financing and partnering options.

Disclaimer*

UK 100

Latest directors dealings